PE20181303A1 - Compuestos que inhiben eif4a y metodos relacionados a los mismos - Google Patents

Compuestos que inhiben eif4a y metodos relacionados a los mismos

Info

Publication number
PE20181303A1
PE20181303A1 PE2018001027A PE2018001027A PE20181303A1 PE 20181303 A1 PE20181303 A1 PE 20181303A1 PE 2018001027 A PE2018001027 A PE 2018001027A PE 2018001027 A PE2018001027 A PE 2018001027A PE 20181303 A1 PE20181303 A1 PE 20181303A1
Authority
PE
Peru
Prior art keywords
compounds
related methods
formula
eif4a
pharmaceutically acceptable
Prior art date
Application number
PE2018001027A
Other languages
English (en)
Inventor
Justin T Ernst
Siegfried H Reich
Paul A Sprengeler
Chinh Tran
Garrick Kenneth PACKARD
Alan Xin Xiang
Christian Nilewski
Theodore Michels
Original Assignee
Effector Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Effector Therapeutics Inc filed Critical Effector Therapeutics Inc
Publication of PE20181303A1 publication Critical patent/PE20181303A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/78—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/153—Ortho-condensed systems the condensed system containing two rings with oxygen as ring hetero atom and one ring with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invencion proporciona sintesis, formulaciones farmaceuticamente aceptables y usos de compuestos de acuerdo con la Formula I, o un estereoisornero, tautomero o sal farmaceuticamente aceptable del mismo. Para los compuestos de formula I, X, Y, R1, R2, R3a, R3b, R4a, R4h y R5 son corno se definen en la memoria descriptiva. Los compuestos de Formula I inventivos son inhibidores de eiF4A y encuentran utilidad en cualquier numero de aplicaciones terapeuticas, que incluyen, pero no se limitan a, tratamiento de inflamacion y diversos canceres.
PE2018001027A 2015-11-25 2016-11-22 Compuestos que inhiben eif4a y metodos relacionados a los mismos PE20181303A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562259828P 2015-11-25 2015-11-25
US201662334149P 2016-05-10 2016-05-10

Publications (1)

Publication Number Publication Date
PE20181303A1 true PE20181303A1 (es) 2018-08-09

Family

ID=58720397

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2018001027A PE20181303A1 (es) 2015-11-25 2016-11-22 Compuestos que inhiben eif4a y metodos relacionados a los mismos

Country Status (22)

Country Link
US (5) US9957277B2 (es)
EP (2) EP3380101B1 (es)
JP (1) JP7105691B2 (es)
KR (1) KR20180096644A (es)
CN (1) CN108601788B (es)
AU (1) AU2016359617B2 (es)
CA (1) CA3006041A1 (es)
CL (1) CL2018001411A1 (es)
CO (1) CO2018006475A2 (es)
DK (2) DK3888658T3 (es)
EA (1) EA037370B1 (es)
ES (1) ES2870037T3 (es)
FI (1) FI3888658T3 (es)
IL (1) IL259433B (es)
MX (1) MX2018006443A (es)
MY (1) MY196749A (es)
PE (1) PE20181303A1 (es)
PH (1) PH12018501073A1 (es)
SG (2) SG11201804132UA (es)
TW (1) TWI731899B (es)
WO (1) WO2017091585A1 (es)
ZA (1) ZA201804070B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015117053A1 (en) 2014-01-31 2015-08-06 Dana-Farber Cancer Institute, Inc. Diaminopyrimidine benzenesulfone derivatives and uses thereof
JP2017504651A (ja) 2014-01-31 2017-02-09 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド ジアゼパン誘導体の使用
EP3750545B1 (en) 2014-11-17 2024-03-27 Cellectar Biosciences, Inc. Phospholipid ether analogs as cancer-targeting drug vehicles
CA2996974A1 (en) 2015-09-11 2017-03-16 Dana-Farber Cancer Institute, Inc. Cyano thienotriazolodiazepines and uses thereof
US10881668B2 (en) 2015-09-11 2021-01-05 Dana-Farber Cancer Institute, Inc. Acetamide thienotriazolodiazepines and uses thereof
AU2016361478B2 (en) 2015-11-25 2020-09-10 Dana-Farber Cancer Institute, Inc. Bivalent bromodomain inhibitors and uses thereof
MX2018006443A (es) * 2015-11-25 2019-08-01 Effector Therapeutics Inc Compuestos que inhiben eif4a y métodos relacionados a los mismos.
JP2019503338A (ja) 2015-11-25 2019-02-07 ギリアド アポロ， エルエルシー ２，４−ジオキソ−１，４−ジヒドロチエノ［２，３−ｄ］ピリミジンの誘導体を含む殺真菌組成物
SI3380479T1 (sl) 2015-11-25 2023-04-28 Gilead Apollo, Llc Triazolni inhibitorji ACC in uporabe le-teh
ES2855348T3 (es) 2015-11-25 2021-09-23 Gilead Apollo Llc Inhibidores de éster ACC y usos de los mismos
JP2019502660A (ja) 2015-11-25 2019-01-31 ギリアド アポロ， エルエルシー ピラゾールａｃｃ阻害剤およびその使用
BR112019023109A2 (pt) * 2017-05-04 2020-05-26 Glenmark Pharmaceuticals S.A. Composto, composição farmacêutica e método para tratar uma doença, distúrbio, síndrome ou afecção mediada por nadph oxidase em um indivíduo
KR102641269B1 (ko) 2017-05-24 2024-02-26 이펙터 테라퓨틱스, 인크. 개선된 항종양 면역 반응을 위한 조성물 및 방법
KR20200123184A (ko) * 2018-02-19 2020-10-28 메모리얼 슬로안 케터링 캔서 센터 증식이상 장애를 치료하기 위한 물질 및 방법
CN109503418B (zh) * 2018-12-11 2021-06-08 河北合佳医药科技集团股份有限公司 一种甲基肼的制备工艺
WO2020172086A1 (en) * 2019-02-18 2020-08-27 The University Of Toledo Targeting lasp1, eif4a1, eif4b, and cxc4 with modulators and combinations thereof for cancer therapy
CN109971762B (zh) * 2019-04-24 2022-12-20 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) 日本血吸虫eIF4A基因的siRNA及其应用
EP4125884A4 (en) * 2020-03-24 2024-04-03 Effector Therapeutics Inc EIF4A INHIBITOR COMBINATIONS
TW202221003A (zh) * 2020-10-28 2022-06-01 大陸商上海翰森生物醫藥科技有限公司 多環類生物調節劑、其製備方法和應用
CN112574078B (zh) * 2020-12-14 2022-09-13 湖南工程学院 2-砜基-2，3-二氢-1-茚酮及其衍生物及合成方法
WO2023030687A1 (en) 2021-09-01 2023-03-09 KHR Biotec GmbH Cyclopenta[4,5]furo[3,2-c]pyridine derivatives as ras inhibitors for use in the treatment of hyperproliferative diseases or genetic disorders
WO2023030685A1 (en) 2021-09-01 2023-03-09 KHR Biotec GmbH (I. GR.) Novel ras inhibitors
CN115448860B (zh) * 2022-09-16 2024-04-02 上海海客宜家生物科技有限公司 一种邻甲硫基苯甲腈的合成方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19934952A1 (de) 1998-07-30 2000-02-03 Novartis Ag Cyclopentabenzofuran-Derivate
DE10356218A1 (de) 2003-12-03 2005-06-30 Bayer Cropscience Ag Verfahren zum Identifizieren von fungizid wirksamen Verbindungen basierend auf Pyruvatkinasen aus Pilzen
CA2560740A1 (en) 2004-03-23 2006-10-06 Trustees Of Boston University Synthesis of rocaglamide natural products via photochemical generation of oxidopyrylium species
DE102004024504A1 (de) 2004-05-18 2006-02-16 Bayer Healthcare Ag Neue Cylopenta[b]benzofuran-Derivate und ihre Verwendung
WO2006007634A1 (en) 2004-07-16 2006-01-26 Cerylid Biosciences Ltd Processes and intermediates
EP1693059A1 (en) 2005-02-22 2006-08-23 Deutsches Krebsforschungszentrum Use of rocaglamide derivatives as NF-AT-specific inhibitors for the treatment of certain inflammatory diseases
CN100418532C (zh) 2005-06-17 2008-09-17 吕志民 治疗多种疾病的NF-κB化合物抑制剂
WO2007139749A2 (en) * 2006-05-22 2007-12-06 Trustees Of Boston University Asymmetric synthesis of rocaglamides via enantioselective photocycloaddition mediated by chiral bronsted acids
EP2189453A1 (en) 2008-11-25 2010-05-26 Université Louis Pasteur Rocaglaol derivatives as cardioprotectant agents
WO2011140334A2 (en) 2010-05-06 2011-11-10 Trustees Of Boston University Compounds, methods of making or identifying compounds, and uses thereof
EP2457907A1 (en) 2010-11-16 2012-05-30 Université de Strasbourg Flavagline derivatives as neuroprotective agents
BR112013014484A2 (pt) * 2010-12-13 2016-07-19 Viamet Pharmaceuticals Inc compostos inibidores de metaloenzimas
WO2013016658A1 (en) 2011-07-27 2013-01-31 The Ohio State University Research Foundation Silvestrol, silvestrol analogs and uses thereof
WO2013170257A1 (en) * 2012-05-11 2013-11-14 Dana-Farber Cancer Institute, Inc. Treating muc1-expressing cancers with helicase inhibitors
WO2015007714A1 (en) 2013-07-17 2015-01-22 Deutsches Krebsforschungszentrum Sensitization of cancer cells to apoptosis induction by flavaglines and 5-hydroxy-flavones
WO2015075165A1 (en) 2013-11-22 2015-05-28 Deutsches Krebsforschungszentrum Translation inhibitors in high-dose chemo- and/or high-dose radiotherapy
FR3023290B1 (fr) 2014-07-04 2016-08-19 Pf Medicament Derives de flavaglines
MX2018006443A (es) 2015-11-25 2019-08-01 Effector Therapeutics Inc Compuestos que inhiben eif4a y métodos relacionados a los mismos.

Also Published As

Publication number Publication date
EP3380101A4 (en) 2019-05-22
US20170145026A1 (en) 2017-05-25
AU2016359617B2 (en) 2022-04-14
FI3888658T3 (fi) 2024-03-22
TW201731832A (zh) 2017-09-16
US20230295179A1 (en) 2023-09-21
EA201891229A1 (ru) 2018-12-28
CN108601788B (zh) 2021-10-22
EA037370B1 (ru) 2021-03-19
CA3006041A1 (en) 2017-06-01
US9957277B2 (en) 2018-05-01
US20230071483A1 (en) 2023-03-09
ZA201804070B (en) 2021-10-27
AU2016359617A1 (en) 2018-07-05
DK3380101T3 (da) 2021-04-26
EP3888658A1 (en) 2021-10-06
IL259433B (en) 2021-05-31
KR20180096644A (ko) 2018-08-29
JP2019500331A (ja) 2019-01-10
EP3380101A1 (en) 2018-10-03
EP3380101B1 (en) 2021-01-27
WO2017091585A1 (en) 2017-06-01
BR112018010235A2 (pt) 2019-03-19
CO2018006475A2 (es) 2018-07-10
EP3888658B1 (en) 2023-12-27
CN108601788A (zh) 2018-09-28
MY196749A (en) 2023-05-03
TWI731899B (zh) 2021-07-01
DK3888658T3 (da) 2024-03-18
SG11201804132UA (en) 2018-06-28
SG10202004793YA (en) 2020-06-29
MX2018006443A (es) 2019-08-01
PH12018501073A1 (en) 2019-01-21
JP7105691B2 (ja) 2022-07-25
IL259433A (en) 2018-07-31
US11440917B2 (en) 2022-09-13
US20200339590A1 (en) 2020-10-29
US10577378B2 (en) 2020-03-03
ES2870037T3 (es) 2021-10-26
US20180298017A1 (en) 2018-10-18
CL2018001411A1 (es) 2018-11-30

Similar Documents

Publication Publication Date Title
PE20181303A1 (es) Compuestos que inhiben eif4a y metodos relacionados a los mismos
CL2018000318A1 (es) Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925)
CL2019000820A1 (es) Compuestos, composiciones y sus usos para inhibir la actividad arginasa. (divisional solicitud 201801134)
EA201891049A1 (ru) Изоиндолиновые, азаизоиндолиновые, дигидроинденоновые и дигидроазаинденоновые ингибиторы mnk1 и mnk2
CO2017000399A2 (es) Inhibidores de cinasa de interacción con proteína cinasa activada por mitógeno (mnk) y métodos relacionados con los mismos
CL2020001218A1 (es) Compuestos útiles para inhibir a cdk7.
ECSP17013903A (es) Protein kinase c inhibitors and methods of their use
DOP2016000085A (es) Amino-heteroaril-benzamidas como inhibidores de cinasa
SV2018005687A (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cancer
NI201600018A (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b.
UY35590A (es) Nuevos compuestos para el tratamiento del cáncer
UY35273A (es) Tiadiazol, análogos del mismo, y métodos para el tratamiento de condiciones relacionadas con defici encia de smn
UY36875A (es) Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades
CO2019009423A2 (es) Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos
CO2017007325A2 (es) 2,4 diamino-quinolina sustituida como nuevos agentes anti-cancerigenos
DOP2016000039A (es) Inhibidores de rorc2 y sus usos
CU20170153A7 (es) Compuestos tricíclicos útiles como inhibidores de la fosfodiesterasa
CO2019002523A2 (es) Inhibidores de dopamina–β–hidroxilasa penetrantes de la barrera hematoencefálica
UY35359A (es) 7-OXO-PIRIDO[2,3-d]PIRIMIDINAS SUSTITUIDAS Y MÉTODOS DE USO
CR20160527A (es) Derivados de carboxamida
UY37729A (es) NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7
CR20160529A (es) Composiciones farmacéuticas para tratar enfermedades infecciosas
EA201891319A1 (ru) Соединения алкилдигидрохинолинсульфонамида
UY36851A (es) Compuestos para uso en aplicaciones antibacterianas
ECSP18056196A (es) Derivados de indano